Download PDF
Thromb Haemost 2009; 101(01): 09-11
DOI: 10.1160/TH08-11-0770
Editorial Focus
Schattauer GmbH

Drug-eluting balloons for percutaneous coronary interventions

Marco Zimarino
1   Institute of Cardiology and Center of Excellence on Aging, “G. d’Annunzio” University, Chieti, Italy
,
Raffaele De Caterina
› Author Affiliations
Further Information

Publication History

Received: 27 November 2008

Accepted: 27 November 2008

Publication Date:
23 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Gruentzig A. Results from coronary angioplasty and implications for the future. Am Heart J 1982; 103: 779-783.
    CrossrefPubMedGoogle Scholar
  • 2 Fox K, Garcia MA, Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341-1381.
    CrossrefPubMedGoogle Scholar
  • 3 Orford JL, Selwyn AP, Ganz P. et al. The comparative pathobiology of atherosclerosis and restenosis. Am J Cardiol 2000; 86: 6H-11H.
    CrossrefPubMedGoogle Scholar
  • 4 Mauri L, Hsieh WH, Massaro JM. et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020-1029.
    CrossrefPubMedGoogle Scholar
  • 5 Finn AV, Kolodgie FD, Harnek J. et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxeleluting stents. Circulation 2005; 112: 270-278.
    CrossrefPubMedGoogle Scholar
  • 6 De Caterina R, Husted S, Wallentin L. et al. Anticoagulants in heart disease: current status and perspectives. Eur Heart J 2007; 28: 880-913.
    CrossrefPubMedGoogle Scholar
  • 7 Herdeg C, Oberhoff M, Baumbach A. et al. Local paclitaxel delivery for the prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000; 35: 1969-1976.
    CrossrefPubMedGoogle Scholar
  • 8 Scheller B, Speck U, Romeike B. et al. Contrast media as carriers for local drug delivery. Successful inhibition of neointimal proliferation in the porcine coronary stent model. Eur Heart J 2003; 24: 1462-1467.
    CrossrefPubMedGoogle Scholar
  • 9 Scheller B, Speck U, Abramjuk C. et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004; 110: 810-814.
    CrossrefPubMedGoogle Scholar
  • 10 Scheller B, Hehrlein C, Bocksch W. et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med 2006; 355: 2113-2124.
    CrossrefPubMedGoogle Scholar
  • 11 Cremers B, Speck U, Kaufels N. et al. Drug-eluting balloon: very short-term exposure and overlapping. Thromb Haemost 2009; 101: 201-206.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Stone GW, Ellis SG, O’Shaughnessy CD. et al. Paclitaxel-eluting stents vs vascular brachytherapy for instent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. J Am Med Assoc 2006; 295: 1253-1263.
    CrossrefPubMedGoogle Scholar
  • 13 Erbel R, Di Mario C, Bartunek J. et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007; 369: 1869-1875.
    CrossrefPubMedGoogle Scholar
  • 14 Ormiston JA, Serruys PW, Regar E. et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008; 371: 899-907.
    CrossrefPubMedGoogle Scholar